However, concerns about the long-term safety of GLP-1 RAs, including serious adverse events, warrant further investigation. While GLP-1 RAs hold promise for treating obesity in PCOS, safety issues may limit their utility. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.